Scarica l'app Stockscreener
53.48
2.96%
1.54
Dopo l'orario di chiusura:
53.00
-0.48
-0.90%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BBIO Giù?
Forum
Previsione
Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie
Hypoparathyroidism Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Bridgebio/Calcil ytix Therapeutics, Ascendis Pharma, EnteraBio, Shire - Barchart.com
Pattern recognition hints at BridgeBio Pharma Inc. upsideForecast Cut & Long Hold Capital Preservation Tips - newser.com
How big funds are accumulating BridgeBio Pharma Inc. (2CL) stockDollar Strength & Consistent Return Investment Signals - newser.com
Real time breakdown of BridgeBio Pharma Inc. stock performanceJuly 2025 Momentum & Short-Term High Return Strategies - newser.com
Why BridgeBio Pharma Inc. (2CL) stock could outperform next yearJuly 2025 Update & Expert Curated Trade Ideas - newser.com
Analyzing drawdowns of BridgeBio Pharma Inc. with statistical toolsTrade Volume Report & Reliable Intraday Trade Alerts - newser.com
What earnings revisions data tells us about BridgeBio Pharma Inc.2025 Market Overview & Weekly Market Pulse Updates - newser.com
How buybacks impact BridgeBio Pharma Inc. stock valueWeekly Trade Analysis & Growth Oriented Trading Recommendations - newser.com
Is BridgeBio Pharma Inc a good long term investmentMarket Sentiment Surveys & Access Free Tools and Start Investing - earlytimes.in
What MACD and RSI say about BridgeBio Pharma Inc.Trade Entry Report & Verified Swing Trading Watchlist - newser.com
Why Is BridgeBio Stock Gaining Monday?BridgeBio Pharma (NASDAQ:BBIO) - Benzinga
Moss Adams Wealth Advisors LLC Has $1.04 Million Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: A Biotech Powerhouse with a 32.50% Potential Upside - DirectorsTalk Interviews
BridgeBio Pharma Says Drug Reduced Death, Hospitalization in Cardiomyopathy Patients After 1 Month - MarketScreener
Will breakout in BridgeBio Pharma Inc. lead to full recovery2025 Market WrapUp & Stepwise Trade Signal Guides - newser.com
What analysts say about BridgeBio Pharma Inc stockEarnings Beat Highlights & Small Budget Investment Tips - earlytimes.in
BridgeBio (BBIO) Unveils Positive Results in ATTRibute-CM Study - GuruFocus
BridgeBio Pharma says Acoramidis reduces CVM or CVH risk by 49% through month 30 - MarketScreener
BridgeBio Pharma Reports Positive Results from ATTRibute-CM Study, Demonstrating Significant Reduction in Cardiovascular Outcomes with Acoramidis - Quiver Quantitative
53 Heart Events Prevented Per 100 Patients: BridgeBio's Acoramidis Shows Powerful Early Benefits in ATTR-CM - Stock Titan
What technical models suggest about BridgeBio Pharma Inc.’s comebackJuly 2025 Review & Consistent Income Trade Ideas - newser.com
BridgeBio Pharma Inc Stock Analysis and ForecastPortfolio Allocation Tips & Smart Beta Strategies That Actually Work - earlytimes.in
Best data tools to analyze BridgeBio Pharma Inc. stockStop Loss & Stepwise Swing Trade Plans - newser.com
H.C. Wainwright Reiterates a Buy on BridgeBio Pharma (BBIO) - MSN
Retirement Income Solutions Inc Acquires Shares of 5,000 BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma’s Encaleret Shows Positive Phase 2 Results, Normalizes Calcium in Post-Surgical Hypoparathyroidism - Yahoo Finance
Atle Fund Management AB Grows Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Assenagon Asset Management S.A. Has $15.13 Million Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Strs Ohio Makes New Investment in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio to Present Additional Cardiovascular Outcomes - GlobeNewswire
BridgeBio Pharma to Present Key Clinical Trial Findings at Heart Failure Society of America Annual Scientific Meeting 2025 - Quiver Quantitative
BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025 - The Manila Times
New Cardiovascular Outcomes Data: BridgeBio's Acoramidis Shows Impact on ATTR-CM Patient Survival - Stock Titan
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Exploring a Biotech Powerhouse with 24% Upside Potential - DirectorsTalk Interviews
Risks To Shareholder Returns Are Elevated At These Prices For BridgeBio Pharma, Inc. (NASDAQ:BBIO) - 富途牛牛
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma, Inc. $BBIO Stock Position Lifted by Intech Investment Management LLC - MarketBeat
Leerink Partners Maintains a Buy on BridgeBio Pharma (BBIO) With a $56 PT - MSN
Fed Watch: Should value investors consider BridgeBio Pharma IncQuarterly Trade Report & Capital Efficient Trading Techniques - خودرو بانک
BridgeBio Pharma (NASDAQ:BBIO) Earns Buy Rating from HC Wainwright - MarketBeat
Aug Mood: What is the Moat Score of BridgeBio Pharma IncWeekly Trade Analysis & Weekly Watchlist for Hot Stocks - خودرو بانک
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
2.95%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):